Eagle Asset Management Inc. Purchases 329,288 Shares of Progyny, Inc. (NASDAQ:PGNY)

Eagle Asset Management Inc. raised its holdings in shares of Progyny, Inc. (NASDAQ:PGNYFree Report) by 102.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 649,897 shares of the company’s stock after buying an additional 329,288 shares during the period. Eagle Asset Management Inc.’s holdings in Progyny were worth $24,163,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. RiverPark Advisors LLC grew its stake in Progyny by 54.0% during the fourth quarter. RiverPark Advisors LLC now owns 1,067 shares of the company’s stock valued at $40,000 after acquiring an additional 374 shares in the last quarter. Acadian Asset Management LLC bought a new position in Progyny during the third quarter valued at $53,000. Parkside Financial Bank & Trust lifted its position in Progyny by 9.3% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,096 shares of the company’s stock valued at $115,000 after purchasing an additional 264 shares during the last quarter. Assetmark Inc. grew its stake in shares of Progyny by 26.8% in the 4th quarter. Assetmark Inc. now owns 3,756 shares of the company’s stock worth $140,000 after buying an additional 793 shares in the last quarter. Finally, Cetera Trust Company N.A bought a new stake in shares of Progyny in the 4th quarter worth about $183,000. 94.93% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on PGNY. Leerink Partnrs reiterated an “outperform” rating on shares of Progyny in a research report on Monday, February 26th. Truist Financial dropped their target price on Progyny from $46.00 to $37.00 and set a “buy” rating for the company in a report on Friday, May 17th. Canaccord Genuity Group dropped their price target on shares of Progyny from $46.00 to $37.00 and set a “buy” rating for the company in a research note on Friday, May 10th. SVB Leerink initiated coverage on Progyny in a research note on Monday, February 26th. They set an “outperform” rating and a $49.00 price target for the company. Finally, BTIG Research reduced their price target on shares of Progyny from $50.00 to $41.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Progyny presently has an average rating of “Moderate Buy” and an average price target of $43.11.

View Our Latest Stock Analysis on PGNY

Progyny Trading Up 1.2 %

Shares of PGNY traded up $0.33 during mid-day trading on Friday, hitting $26.95. The company’s stock had a trading volume of 987,473 shares, compared to its average volume of 1,631,927. The company’s 50-day moving average is $31.91 and its 200-day moving average is $35.21. The firm has a market capitalization of $2.57 billion, a price-to-earnings ratio of 44.18, a PEG ratio of 1.85 and a beta of 1.51. Progyny, Inc. has a 52-week low of $23.90 and a 52-week high of $44.95.

Progyny (NASDAQ:PGNYGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.14 by $0.03. Progyny had a return on equity of 11.61% and a net margin of 5.53%. The firm had revenue of $278.08 million during the quarter, compared to analyst estimates of $289.41 million. During the same period in the previous year, the company posted $0.18 EPS. The business’s revenue for the quarter was up 7.6% compared to the same quarter last year. As a group, sell-side analysts predict that Progyny, Inc. will post 0.69 earnings per share for the current fiscal year.

Insider Activity

In related news, President Michael E. Sturmer sold 6,395 shares of Progyny stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $37.60, for a total value of $240,452.00. Following the completion of the sale, the president now directly owns 384,553 shares in the company, valued at approximately $14,459,192.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, President Michael E. Sturmer sold 6,395 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $37.60, for a total value of $240,452.00. Following the transaction, the president now owns 384,553 shares in the company, valued at approximately $14,459,192.80. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Chairman David J. Schlanger sold 71,272 shares of the business’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $37.80, for a total transaction of $2,694,081.60. Following the transaction, the chairman now owns 86,312 shares of the company’s stock, valued at $3,262,593.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 102,770 shares of company stock worth $3,853,985. Corporate insiders own 12.30% of the company’s stock.

About Progyny

(Free Report)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Articles

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNYFree Report).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.